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score.(Gleason score, prostate-specific antigen, tumor stage) and fractionation schedule.
Immunohistochemistry was used to stain diagnostic biopsy specimens for Ki67, which
were scored using the unweighted global method. Conditional logistic regression
models estimated the prognostic value of mean and maximum Ki67 scores on BCR
risk. Biomarkerefractionation interaction terms determined whether Ki67 was predic-
tive of BCR by fractionation.
Results: Using 173 matched pairs, the median for mean and maximum Ki67 scores
were 6.6% (interquartile range, 3.9%-9.8%) and 11.0% (interquartile range, 7.0%-
15.0%) respectively. Both scores were significant predictors of BCR in models
adjusted for established prognostic factors. Conditioning on matching variables and
age, the odds of BCR were estimated to increase by 9% per 1% increase in mean
Ki67 score (odds ratio 1.09; 95% confidence interval 1.04-1.15, PZ .001). Interaction
terms between Ki67 and fractionation schedules were not statistically significant.
Conclusions: Diagnostic Ki67 did not predict BCR according to fractionation
schedule in CHHiP; however, it was a strong independent prognostic factor for
BCR.  2018 The Author(s). Published by Elsevier Inc. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Prostate cancer (PCa) is the second most common cancer
worldwide for males; more than 1.11 million new cases were
diagnosed in 2012 (1). In the developed world, increased
prostate-specific antigen (PSA) testing means that most pa-
tients are diagnosed with localized disease, for which
external beam radiation therapy (EBRT), brachytherapy, and
prostatectomy are important radical treatment options.
Recurrence rates after EBRT for localized PCa vary
considerably, from approximately 10% to 40-50% (2, 3).
Recurrences are inadequately predicted using current
prognostic algorithms that incorporate Gleason grade,
T stage, and presenting PSA level. Identification of prog-
nostic biomarkers to aid treatment stratification would
therefore be clinically useful.
In addition, EBRT is delivered using a uniform frac-
tionation schedule for all localized PCa (ie, a “one size fits
all approach”). This is despite a wide variation in the
biology of localized PCa (4), including proliferation rate
(5). A personalized approach to fractionation therefore of-
fers considerable potential to improve therapeutic out-
comes. Biomarkers predicting sensitivity to radiation
therapy fraction size have recently been identified as a key
area for radiobiological research (6).
There is a tight inverse association between the prolifer-
ative indices of normal tissues and fractionation sensitivity.
Tissues with high proliferation indices, such as gastrointes-
tinal mucosa and epidermis, are insensitive to fraction size.
In contrast, late-reacting normal tissues, such as kidney, have
low proliferative indices and are very sensitive to fraction
size (7, 8). This study tests the hypothesis that the same
association between proliferative indices and fractionation
sensitivity in normal tissues extends to localized PCa.The CHHiP trial randomly assigned 3216 men to con-
ventional fractionation (74 Gy in 37 fractions over
7.4 weeks) or 1 of 2 hypofractionated schedules (60 Gy in
20 fractions over 4 weeks or 57 Gy in 19 fractions over
3.8 weeks) (3). Trans-CHHiP is the main translational
substudy within CHHiP; tissue blocks from more than 2000
patients have been collected. It provides an excellent op-
portunity to test the above hypothesis. The expectation is
that highly proliferative cancers will show insensitivity to
fraction size and be more likely to relapse after the reduced
total dose in hypofractionated (>2 Gy) schedules. In
contrast, slowly proliferating tumors are expected to be
sensitive to fraction size, hence more likely to relapse after
conventional fractionation (2 Gy) schedules (7).Methods and Material
Study design
A matched caseecontrol methodology was used to select
study participants. The study was approved by the London
Multi-centre Research Ethics Committee (04/MRE02/10)
and the local ethics committees of all participating centers.
Patients experiencing recurrence (cases) were matched 1:1
to patients without recurrence (controls). Matching criteria
included fractionation schedule (74 Gy/37 fractions, 60 Gy/
20 fractions or 57 Gy/19 fractions) and established prog-
nostic factors including PSA (<10/10-20/>20 ng/mL),
Gleason grade (3 þ 3/3 þ 4/4 þ 3/4 þ 4), and T stage
(T1/T2/T3). All tissue samples were centrally reviewed by
a specialist uropathologist (C.M.C.), including assignment
of Gleason grade according to recent International Society
of Urological Pathology and World Health Organization
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grade was used for matching.
Immunohistochemistry staining and scoring
Full-face sections from the diagnostic biopsy blocks were
used for immunohistochemistry staining. This decision fol-
lowed a pilot study that demonstrated construction of tissue
microarray, using the checkerboard technique (11), resulted
in inadequate tumor cellularity (Tables E1 and E2; available
online at www.redjournal.org). Immunohistochemistry
staining methods are outlined in the Appendix (available
online at www.redjournal.org). All slides were scored using
bright-field microscopy by 2 independent investigators
blinded to recurrence status and fractionation schedule. The
CK5/6 basal marker distinguished preinvasive from invasive
disease. Prostatic intraepithelial neoplasia and intraductal
carcinoma were not scored. A minimum of 100 tumor cells
were required to score each case.
The unweighted global assessment of Ki67 developed by
the International Ki67 Working Group was used to score all
prostate biopsies (12, 13). This includes assessment of
intratumoral spatial heterogeneity, which is well recognized
in localized PCa (14). The global assessment has met
prespecified criteria for scoring reproducibility in an
international phase 3 study using core biopsies of breast
tumors (13). It involves counting 100 tumor cells in up to 4Fig. 1. Scoring Ki67 using the global unweighted method. Thi
proliferation tumor; therefore, high-power fields were selected for
this case the numbers of positive staining cells were as follows: fi
100. This gives a mean Ki67 score of 20.5% and a maximum Khigh-power fields to derive a mean Ki67 score (Fig. 1).
Fields are chosen following an assessment of overall het-
erogeneity in staining. The final mean Ki67 score consisted
of the average of the 2 scoring investigators’ mean Ki67
scores for each case. Maximum Ki67 was assessed by 1
investigator and consisted of the highest-scoring individual
field (Fig. 1). This was included because the highest pro-
liferative tumor area may be important for radiation therapy
response.
All cases with a discrepancy in initial mean Ki67 score
>10% were rescored (15). Further rescores were carried
out if the discrepancy remained >10%.
Study endpoints
Mean and maximum Ki67 scores were evaluated. Recur-
rence was defined as patients with biochemical (16) or
clinical failure after radiation therapy (BCR). Patients
experiencing BCR within 2 years of radiation therapy
commencement were excluded because they are more
likely to have developed distant metastases than local
recurrence due to radiation therapy failure (2). All data
pertaining to recurrence was taken from a CHHiP data
snapshot (November 9, 2015) in which median follow-up
was 62.4 months (interquartile range, 53.9-77.0 moths).
Nonrecurrence was defined in patients with no evidence of
BCR alive at the data snapshot.s case contained 50% high proliferation tumor and 50% low
2 highly proliferative areas and 2 low proliferative areas. In
eld 1, 39/100; field 2, 33/100; field 3, 5/100; and field 4, 5/
i67 score of 39%.
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Agreement in Ki67 scores between the 2 scoring in-
vestigators was assessed using Bland-Altman plots to
measure the difference between the scores versus the mean
of the mean Ki67 scores (17). The concordance correlation
coefficient was used to quantify agreement. The difference
in the mean Ki67 scores (mean and maximum) between the
matched cases and controls by fractionation schedule was
compared using paired t tests.
Both Ki67 endpoints were analyzed as continuous
variables to maximize statistical power (18). Multivariable
conditional logistic regression models were fitted to esti-
mate the prognostic value of Ki67 on the risk of BCR,
using the entire Trans-CHHiP caseecontrol study cohort.
To determine whether Ki67 predicted BCR by fraction-
ation, a biomarkerefractionation interaction term was
included. Three comparisons were undertaken to avoid
confounding by different recurrence rates across trial arms
(74 Gy/37 fractions vs 60 Gy/20 fractions, 74 Gy/37
fractions vs 57 Gy/19 fractions, and 60 Gy/20 fractions vs
57 Gy/19 fractions). Based on an alpha of 0.017, we
estimated a power of 75.5%, 74.8%, and 70.0% to detect
an interaction between each fractionation schedule and
Ki67, respectively (Table E3; available online at www.
redjournal.org).
All statistical analysis was conducted using STATA
version 13.0 (StataCorp, College Station, TX) and R
(version i3863.3.3; R Foundation for Statistical Computing,
Vienna).Table 1 Distribution of the matching variables and age, according
Variable










<10 17 17 29.3 20
10-<20 37 37 63.8 27
20 4 4 6.9 5
Tumor stage
T1 11 11 19.0 8
T2 42 42 72.4 38
T3 5 5 8.6 6
Gleason score
6 6 6 10.3 5
3þ4 31 31 53.4 30
4þ3 16 16 27.6 10
8 5 5 8.6 7
Age at randomization
(y), mean (SD)
69.4 (6.3) 69.8 (6.6) 68.9 (5
PSA (ng/mL)
median (IQR)
12 (8.9-15.8) 11.9 (9.1-16.2) 12.2 (8.6-
Abbreviations: IQR Z interquartile range; PSA Z prostate-specific antigenResults
Patient characteristics
A total of 437 cases were assessed by both scoring in-
vestigators. Ki67 scores were provided by both in-
vestigators in 400 cases; in 37 cases there was insufficient
tumor present. The final matched dataset comprised 173
patients with BCR after start of radiation therapy (cases)
and 173 patients without recurrence (controls). Matching
was achieved to 100% of relevant criteria in all cases
analyzed. Fifty-four patients were excluded because they
did not have an appropriate match; these were usually
controls with no available matching case. Table 1 shows the
distribution of the matching variables and age for the
controls and cases.Agreement in Ki67 scores
Of the total of 400 cases scored by both investigators, in 12
cases (3.0%) the difference in mean Ki67 between the 2
scoring investigators was 10% (interquartile range,
11.8%-15.1%). These were rescored by both scoring in-
vestigators. All rescores were within the required <10%
discrepancy.
Scatter plots comparing each scoring investigator’s
final scores, and Bland-Altman plots comparing the
difference in final score versus the mean Ki67, are shown
in Figure 2 (original scores, Fig. E1; available online atto fractionation schedule











20 38.5 33 33 52.4
27 51.9 26 26 41.3
5 9.6 4 4 6.3
8 15.4 20 20 31.7
38 73.1 35 35 55.6
6 11.5 8 8 12.7
5 9.6 8 8 12.7
30 57.7 30 30 47.6
10 19.2 15 15 23.8
7 13.5 10 10 15.9
.4) 68.0 (5.8) 70.1 (6.1) 68.4 (6.2)
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Fig. 2. (A) Scatter plot showing concordance in final mean Ki67 between independent scoring investigators. (B) Brand-
Altman plot showing difference in final scores between investigator 1 and investigator 2 versus mean scores.
Table 2 Odds ratio (OR) for BCR estimated by multivari-
able conditional logistic regression models (n Z 346) using
Ki67 as a continuous variable, for mean and maximum Ki67
Ki67 biomarker OR* 95% CI P
Mean Ki67 scores 1.09 1.04-1.15 .001
Maximum Ki67 scores 1.05 1.01-1.09 .006
Abbreviations: BCRZ biochemical or clinical failure after radiation
therapy; CI Z confidence interval.
* Odds ratios are adjusted for the matching variables and age at
randomization.
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the difference in score tended to increase as the mean Ki67
score increased. The overall agreement was considered to
be good, with a concordance correlation coefficient of 0.74
(95% confidence interval [CI] 0.70-0.78, P < .001) for the
final scores. For the original scores before rescore, the
concordance correlation coefficient was 0.63 (95% CI 0.58-
0.68, P < .001).
Prediction of biochemical/clinical recurrence
Multivariable conditional logistic regression models using
the entire Trans-CHHiP caseecontrol study sample showed
that both mean Ki67 and maximum Ki67 were statistically
significant predictors of BCR (Table 2 and Table E4;
available online at www.redjournal.org). For each unit in-
crease in mean Ki67 the odds of BCR is estimated to in-
crease by 9% (odds ratio 1.09, 95% CI 1.04-1.15,
P Z .001), having adjusted for matching variables and age.
It is clinically relevant that the prediction of recurrence by
mean Ki67 is independent of Gleason grade. The lack of
correlation between mean Ki67 and Gleason grade is also
displayed in the box and whisker plot (Fig. 3). For the
maximum Ki67, the odds of BCR were estimated to in-
crease by 5% for each unit increase in the maximum Ki67
score (odds ratio 1.05, 95% CI: 1.01-1.09, P Z .006) in the
multivariable model.
Prediction of fraction sensitivity
The results of interaction tests between either mean or
maximum Ki67 and fractionation schedule were not sta-
tistically significant for all comparisons (Table 3 and Table
E4; available online at www.redjournal.org). The distribu-
tion of mean and maximum Ki67 scores according to
fractionation schedule and recurrence status, including a
statistical comparison of the difference between cases andcontrols within fractionation arms, is shown in Figure E2
(available online at www.redjournal.org).
Discussion
This study measures Ki67 staining indices in localized PCa
treated with different radiation therapy fractionation
schedules. It indicates that the global unweighted method
for scoring Ki67 can be used with good agreement between
independent scoring investigators without prior experience
of this method. To our knowledge this is the first report
using the global unweighted method in PCa. However, it is
an established method to aid treatment stratification in
breast cancer (19), in which Ki67 is used clinically to
distinguish between low proliferation luminal A and higher
proliferative luminal B breast cancer subtypes (20).
The statistically significant association between mean
Ki67 and prediction of BCR has potential clinical appli-
cation. Our results require external validation in additional
patient cohorts, with particular attention to the spectrum of
Ki67 expression in different risk groups and a rigorous
assessment of scoring concordance in prostate biopsies
across different centers. Patients with high mean Ki67 but
otherwise lower risk factors could be recommended longer
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mean Ki67 scores
1.12 (-0.52-2.76), P = .18
2.55 (0.66-4.43), P = .009
1.51 (0.06-2.95), P = .04
Mean difference* (95% CI)
Fig. 3. Box and whisker plot showing relationship between mean Ki67 and Gleason grade group.
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Patients with low mean Ki67 could be reassured that they
are likely to have a good prognosis and might be candidates
for studies of reduced ADT. This study suggests that Ki67
is of maximal predictive benefit when used as a continuous
variable; this method of stratification is used effectively in
the clinic for Ki67 and other expression profiling-based
algorithms (19, 22).
Our exclusion of patients with BCR less than 2 years
after radiation therapy means the estimates of the predictive
value of Ki67 are likely to be conservative. Maximum Ki67
was also a statistically significant predictor of BCR, which
is worthy of further study because a single-field assessment
of 100 cells is quicker than 4 fields for mean Ki67.
The apparent lack of interaction between Ki67 and
fractionation schedule also has clinical implications. The
range of proliferative indices seen indicates that the pre-
dominantly intermediate-risk PCa included in the trial are
usually slowly proliferative. However, when including
those cancers showing relatively high proliferation rates,
there was no suggestion of a detriment using hypofractio-
nated radiation therapy schedules giving 3 Gy per fraction.
Other tumor types encompass wider ranges in proliferation
and show higher average proliferation (7). Our resultsTable 3 Odds ratio for BCR estimated from multivariable
conditional logistic regression models without and with inter-









74 Gy & 60 Gy Mean Ki67 1.09 1.02-1.17 .007 .26
74 Gy & 57 Gy Mean Ki67 1.07 1.01-1.14 .03 .59
60 Gy & 57 Gy Mean Ki67 1.11 1.04-1.19 .001 .59
Abbreviations as in Table 2.
Odds ratios are adjusted for matching variables and age at
randomisation.
* P value for the interaction between the mean Ki67 scores and
fractionation schedules.should not be interpreted as demonstrating a general lack of
association between proliferation and fraction sensitivity.
An important confounding factor may be the complex
interplay between fraction sensitivity and overall treatment
time (23). Additionally, we acknowledge that the statistical
power of tests of interaction are low and that a relatively
small proportion of high-risk PCa were included in CHHiP.
Of 3216 patients recruited to CHHiP, 3112 (96.7%)
were treated with ADT from just after their diagnostic
biopsy until completion of radiation therapy. Androgen-
deprivation therapy may modulate fraction sensitivity
because it can markedly reduce proliferation and affect
repair of double-stranded DNA breaks (24). Androgen-
deprivation therapy can also inhibit the cell cycle at the
G1/S checkpoint as part of induction of senescence (25, 26).
This inhibition could restrict use of double-stranded DNA
repair pathway homologous recombination, which operates
exclusively in S and G2 and is thought to mediate resistance
to fraction sensitivity (27, 28). Cells would instead rely on
error-prone nonhomologous end-joining, which operates
throughout the cell cycle and is important for fraction
sensitivity (27, 28). In the PROFIT trial of radiation therapy
fractionation, men did not receive ADT and outcomes were
similar to those in CHHiP (29). This suggests that ADT
does not have a major impact on average fraction sensitivity
in PCa; however, ADT may have confounded the interaction
between proliferation and BCR according to fractionation
schedule in our study.
Our results are supported by a recent report by Pollack
et al (30). In this, a single cut-point (11.3%) was used to
score Ki67, fractionation schedules differed from those in
our study, and there were fewer failure events. However,
Ki67 demonstrated independent prediction of prognosis and
did not predict fraction sensitivity. It is relevant that Ki67
immunohistochemistry is routinely available and affordable
for most pathology laboratories, and automated scoring
algorithms are showing potential clinical applicability (31).
This study assessing Ki67 in patients treated with
different radiation therapy fractionation schedules reaches
Volume 101  Number 2  2018 Ki67 to predict recurrence and fraction sensitivity 3152 conclusions. First, it does not suggest that there is a
detriment to using hypofractionated radiation therapy
schedules in PCa showing relatively high proliferation.
Second, Ki67 is a highly statistically significant biomarker
predicting recurrence, independent of established prog-
nostic factors. Because localized PCa shows diverse clinical
outcomes, Ki67 has a potential clinical application to guide
treatment stratification.References
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